

### AMENDMENTS TO THE CLAIMS

1. (Canceled)
2. (Original) A subgenomic replicon of dengue virus origin comprising a deletion for the sequence coding for PreM and E structural proteins ( $\Delta$ ME).
- 3.-7. (Canceled)
8. (Original) A subgenomic replicon of dengue virus type 2 origin comprising a deletion for the sequence coding for PreM and E structural proteins ( $\Delta$ ME).
- 9.-16. (Canceled)
17. (Currently Amended) A subgenomic replicon of dengue virus origin comprising a deletion for the sequence coding for C, PreM, and E structural proteins ( $\Delta$ CME), or for PreM and E structural proteins ( $\Delta$ ME), ~~or for E structural protein ( $\Delta$ E), which is adapted to receive at least a nucleotide sequence without disrupting its replication capabilities.~~
18. (Currently Amended) A vaccine comprising a subgenomic replicon of dengue virus origin which comprises a deletion for the sequence coding for C, PreM, and E structural proteins ( $\Delta$ CME), or for PreM and E structural proteins ( $\Delta$ ME), ~~or for E structural protein ( $\Delta$ E), optionally which is adapted to receive at least a nucleotide sequence without disrupting its replication capabilities, and a pharmaceutically acceptable carrier.~~
19. (Currently Amended) A therapeutic comprising a subgenomic replicon of dengue virus origin which comprises a deletion for the sequence coding for C, PreM, and E structural proteins ( $\Delta$ CME), or for PreM and E structural proteins ( $\Delta$ ME), ~~or for E structural protein ( $\Delta$ E), optionally which is adapted to receive at least a nucleotide sequence without disrupting its replication capabilities, and a pharmaceutically acceptable carrier.~~
20. (Currently Amended) A dengue virus like particle comprising a subgenomic replicon of dengue virus origin which comprises a deletion for the sequence coding for C, PreM, and E structural proteins ( $\Delta$ CME), or for PreM and E structural proteins ( $\Delta$ ME), ~~or for E structural protein ( $\Delta$ E), optionally which is adapted to receive at least a nucleotide sequence without disrupting its replication capabilities, and each of the structural proteins of the homologous dengue virus wherein said structural proteins encapsulate said subgenomic replicon.~~
21. - 24. (Canceled)

25. (New) A replicon of dengue virus origin comprising a deletion in a polynucleotide encoding a PreM structural protein and a deletion in a polynucleotide encoding an E structural protein.

26. (New) The replicon of Claim 25, wherein the dengue virus is a dengue type 1 virus.

27. (New) The replicon of Claim 25, wherein the dengue virus is a dengue type 2 virus.

28. (New) The replicon of Claim 25, wherein the dengue virus is a dengue type 3 virus.

29. (New) The replicon of Claim 25, wherein the dengue virus is a dengue type 4 virus.

30. (New) The replicon of Claim 25, wherein the virus comprises a deletion in a polynucleotide encoding a C structural protein.

31. (New) The replicon of Claim 30, comprising a deletion of the entire polynucleotide encoding the C structural protein.

32. (New) The replicon of Claim 25, comprising a deletion of the entire polynucleotide encoding the PreM structural protein.

33. (New) The replicon of Claim 25, comprising a deletion of the entire polynucleotide encoding the E structural protein.

34. (New) The replicon of Claim 25, wherein said replicon comprises a heterologous polynucleotide.

35. (New) The replicon of Claim 34, wherein said heterologous polynucleotide encodes an HIV protein.

36. (New) A vaccine comprising the replicon of Claim 25.